Abeona Therapeutics Inc.
| NASDAQ: ABEO | Healthcare / Biotechnology / USA |
| 4.17 | -0.0800 | -1.88% | Vol 65.54K | 1Y Perf 24.63% |
| Oct 4th, 2023 16:00 DELAYED |
| BID | 4.14 | ASK | 4.30 | ||
| Open | 4.25 | Previous Close | 4.25 | ||
| Pre-Market | - | After-Market | 4.22 | ||
| - - | 0.05 1.20% |
| Target Price | 22.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 427.58 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -100/-100/-100 | Value Ranking | + 34.95 | |
| Insiders Value % 3/6/12 mo. | -100/-100/-100 | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -100/-100/-100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 54.85 | Earnings Rating | Strong Buy | |
| Market Cap | 103.23M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.05 | Standard Deviation | 0.25 | |
| Beta | 1.26 |
Today's Price Range 4.144.35 | 52W Range 2.195.80 | 5 Year PE Ratio Range -9.50-2.90 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 6.11% | ||
| 1 Month | -0.71% | ||
| 3 Months | -4.14% | ||
| 6 Months | 48.40% | ||
| 1 Year | 24.63% | ||
| 3 Years | -84.70% | ||
| 5 Years | -98.55% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -37.17 | |||
ROE last 12 Months | -214.63 | |||
ROA (5Y Avg) | -49.94 | |||
ROA last 12 Months | -127.57 | |||
ROC (5Y Avg) | -45.02 | |||
ROC last 12 Months | -161.56 | |||
Return on invested Capital Q | -35.92 | |||
Return on invested Capital Y | -63.62 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -0.20 | ||||
| 3.45 | ||||
| 39.05 | ||||
| 30.00 | ||||
| -1.80 | ||||
| -10.76 | ||||
| 3.45 | ||||
| 0.90 | ||||
| 43.37M | ||||
| Forward PE | -2.37 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.50 | ||||
| 2.00 | ||||
| 0.30 | ||||
| 0.54 | ||||
| -135.40 | ||||
| Leverage Ratio | 2.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 92.00 | ||||
| -1 947.30 | ||||
| -1 837.60 | ||||
| -2 180.30 | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.35M | ||||
| 0.08 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.66 | -0.44 | 33.33 |
| Q01 2023 | -0.68 | -0.54 | 20.59 |
| Q03 2022 | -1.78 | -1.48 | 16.85 |
| Q02 2022 | -1.25 | -2.08 | -66.40 |
| Q01 2022 | -2.00 | -2.50 | -25.00 |
| Q04 2021 | -3.25 | -3.50 | -7.69 |
| Q03 2021 | -4.00 | -4.00 | 0.00 |
| Q02 2021 | -4.00 | -4.00 | 0.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 9/2023 QR | -0.53 | 13.11 | Positive |
| 12/2023 QR | -0.53 | 14.52 | Positive |
| 12/2023 FY | -1.99 | 19.76 | Positive |
| 12/2024 FY | -1.77 | 23.38 | Positive |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -0.53 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 65.54K |
| Shares Outstanding | 24.76K |
| Shares Float | 23.94M |
| Trades Count | 538 |
| Dollar Volume | 277.83K |
| Avg. Volume | 148.86K |
| Avg. Weekly Volume | 181.05K |
| Avg. Monthly Volume | 130.05K |
| Avg. Quarterly Volume | 135.49K |
Abeona Therapeutics Inc. (NASDAQ: ABEO) stock closed at 4.17 per share at the end of the most recent trading day (a -1.88% change compared to the prior day closing price) with a volume of 65.54K shares and market capitalization of 103.23M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 90 people. Abeona Therapeutics Inc. CEO is Vishwas Seshadri.
The one-year performance of Abeona Therapeutics Inc. stock is 24.63%, while year-to-date (YTD) performance is 35.39%. ABEO stock has a five-year performance of -98.55%. Its 52-week range is between 2.19 and 5.8, which gives ABEO stock a 52-week price range ratio of 54.85%
Abeona Therapeutics Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 3.45, a price-to-sale (PS) ratio of 39.05, a price to cashflow ratio of 30.00, a PEG ratio of -, a ROA of -127.57%, a ROC of -161.56% and a ROE of -214.63%. The company’s profit margin is -%, its EBITDA margin is -1 837.60%, and its revenue ttm is $1.35 Million , which makes it $0.08 revenue per share.
Of the last four earnings reports from Abeona Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.53 for the next earnings report. Abeona Therapeutics Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Abeona Therapeutics Inc. is Strong Buy (1), with a target price of $22, which is +427.58% compared to the current price. The earnings rating for Abeona Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Abeona Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Abeona Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 19.87, ATR14 : 0.35, CCI20 : 63.46, Chaikin Money Flow : -0.18, MACD : 0.05, Money Flow Index : 46.60, ROC : 5.46, RSI : 57.73, STOCH (14,3) : 68.42, STOCH RSI : 1.00, UO : 39.64, Williams %R : -31.58), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Abeona Therapeutics Inc. in the last 12-months were: Alvino Mark (Sold 887 shares of value $2 883 ), Amoroso Michael (Sold 1 608 shares of value $4 513 ), Brendan M. O'Malley (Buy at a value of $48 295), Joseph Vazzano (Buy at a value of $10 000), Michael Amoroso (Sold 268 shares of value $624 )
Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases.
CEO: Vishwas Seshadri
Telephone: +1 646 813-4701
Address: 1330 Avenue of the Americas, New York 10019, NY, US
Number of employees: 90
